Matica Submits Confirmation of Readiness for Dorval Facility

February 21, 2018 – Toronto, Ontario – Matica Enterprises Inc. (MMJ–CSE) (39N – Frankfurt) (MQPXF – OTC PINK) (“Matica” or the “Company”) announces that further to our January 26, 2018 News Release, the company has completed all adjustments necessary to ensure that the facility in Dorval Quebec should meet Health Canada’s stated revised requirements as per Health Canada’s January 25, 2018 announcement.  

Management is pleased to announce that RoyalMax Biotechnology Canada Inc. (“RoyalMax”) has submitted the Confirmation of Readiness for a License under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) to Health Canada for the production facility in Dorval, including the Photographic-Evidence video to Health Canada to request a cultivation license.


For more information on Matica please visit the website at:


On behalf of the Board of Directors



/s/Boris Ziger

Boris Ziger, CEO & Chairman


The Company’s filings are available for review at and

For further information, please contact Boris Ziger, Chief Executive Officer, at:

Telephone: 416-304-9935




Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at

The CSE has not reviewed, approved or disapproved the content of this press release.